Vera Therapeutics (VERA) awards director 17,084 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Vera Therapeutics director Michael Morrissey received a grant of stock options covering 17,084 shares of Class A Common Stock. The options have a per-share exercise price of $34.35 and expire in 2036. They vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, with full vesting upon a change in control if he remains in service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
MORRISSEY MICHAEL
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 17,084 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 17,084 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 17,084 options
Exercise price: $34.35 per share
Underlying shares: 17,084 shares
+3 more
6 metrics
Option grant size
17,084 options
Stock Option (right to buy) granted to director
Exercise price
$34.35 per share
Conversion or exercise price of the options
Underlying shares
17,084 shares
Class A Common Stock underlying the options
Post-grant derivative holdings
17,084 options
Total derivative shares following transaction
Option expiration
May 20, 2036
Expiration date of the stock options
Vesting end reference year
2027
Earlier of first anniversary or 2027 annual stockholder meeting
Key Terms
Stock Option (right to buy), Class A Common Stock, change in control, continuous service
4 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
Class A Common Stock financial
"underlying_security_title: "Class A Common Stock""
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
change in control financial
"shares will vest in full upon a change in control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
continuous service financial
"subject to the Reporting Person's continuous service through such vesting date"
FAQ
What insider transaction did Vera Therapeutics (VERA) report for Michael Morrissey?
Vera Therapeutics reported that director Michael Morrissey received a grant of stock options covering 17,084 shares. These options are a compensation award, not an open-market purchase, and give him the right to buy Class A Common Stock at a fixed exercise price in the future.
What is the exercise price and expiration for Michael Morrissey’s Vera Therapeutics options?
The granted options have an exercise price of $34.35 per share and expire in 2036. This means Morrissey can choose to buy 17,084 shares at $34.35 any time before the May 20, 2036 expiration date, once the options have vested under the award terms.
How and when do Michael Morrissey’s Vera Therapeutics stock options vest?
The options vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting. Vesting is conditioned on Morrissey’s continuous service, and all options also vest fully upon a change in control if he remains in service through that date.